INNsight Newsletter
Welcome to the December 2022 edition of INNsight Newsletter, brought to you by IQVIA's Global Market Insights. This month we are sharing with you the latest data analytics and intelligence, in the following articles and white paper.
The Advancement of HIV Treatment
The treatment of HIV has shifted drastically since the discovery of antiretroviral therapy (ART) in the early 1990s and the subsequent development of optimal multiple drug regimens. In countries where treatment is easily accessible, the disease has now become a chronic condition with patients reaching near average life expectancy. A typical initial HIV treatment regimen involves a three-drug regimen from at least two drug classes and whilst it is not curative, the treatment drastically reduces virus levels and the risk of transmission. Read more
领英推荐
M&A Activity Slows in 2022 as the Pandemic Biotech Boom Fades
After rebounding in 2021 following the challenges caused by the COVID-19 pandemic, M&A dealmaking took a surprising turn in the first half of 2022 with a significant decline in activity, both in terms of deal volume and value, amid challenging market conditions and escalating geopolitical tensions. This reduced appetite for M&A continued into Q3 2022 as ongoing uncertainties led risk-averse pharmaceutical companies to enter smaller scale, asset-driven acquisitions opposed to big-ticket transformational buyouts.?Read more
Overcoming Pharma’s Launch Performance Problem
This paper explores pharma's launch performance problem and the challenges of the new launch environment. Immediate environmental impact such as lockdowns have resolved, but patient backlogs, changes in healthcare professional (HCP) engagement and budget constraint will impact for years. For launch success in this environment, companies must have a clear understanding of these evolving dynamics and act early to adapt their launch plans?to evolving patient, physician, and payor needs.??Read more
Please note that this is an extract of the INNsight Newsletter. If you want to access the full version and receive the upcoming editions, sign up here .?